Patents Assigned to Genentech
  • ASSAYS AND METHODS USING BIOMARKERS
    Publication number: 20130072429
    Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of GalNac-T related molecules, such as GalNac-T14 or GalNac-T3, is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Kits and articles of manufacture are also provided.
    Type: Application
    Filed: April 11, 2012
    Publication date: March 21, 2013
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Klaus W. Wagner
  • ANTIBODY FORMULATIONS
    Publication number: 20130071384
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: October 25, 2012
    Publication date: March 21, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • Anti-ligand (thromobpoietin) antibodies
    Patent number: 8399250
    Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocyte progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.
    Type: Grant
    Filed: April 27, 1995
    Date of Patent: March 19, 2013
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Frederic J. De Sauvage
  • Antibodies to EGFL7 and methods for their use
    Patent number: 8398976
    Abstract: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: March 19, 2013
    Assignee: Genentech, Inc.
    Inventors: Weilan Ye, Maike Schmidt, Jo-Anne Hongo, Yan Wu
  • Antibody modulators of hepatocyte growth factor activator
    Patent number: 8399629
    Abstract: The invention provides methods and compositions for modulating hepatocyte growth factor activator function.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: March 19, 2013
    Assignee: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Yan Wu
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 8398982
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. TAT113 polypeptides comprising the amino acid sequence of SEQ ID NO: 2 are disclosed. Antibodies that bind TAT113 polypeptides, including monoclonal, chimeric, humanized, single chain, and other antibodies, and fragments thereof, are disclosed. Methods of identifying antibodies that bind epitopes bound by such antibodies, including the antibodies produced by hybridoma cell lines disclosed in the application, are provided, wherein the ability of one antibody to block the binding of another antibody to a TAT113 polypeptide indicates that one antibody binds to an epitope bound by the other antibody.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: March 19, 2013
    Assignee: Genentech, Inc.
    Inventors: Patrick Dowd, Gretchen Frantz, Paul Polakis, Victoria Smith, Susan D. Spencer, Thomas D. Wu, Zemin Zhang
  • 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulene compounds
    Patent number: 8399690
    Abstract: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: March 19, 2013
    Assignees: Genentech, Inc., F. Hoffman-La Roche Inc.
    Inventors: Steven Do, Richard Goldsmith, Tim Heffron, Aleksandr Kolesnikov, Steven Staben, Alan G. Olivero, Michael Siu, Daniel P. Sutherlin, Bing-Yan Zhu, Paul Goldsmith, Tracy Bayliss, Adrian Folkes, Neil Pegg
  • UCP4
    Publication number: 20130066052
    Abstract: The present invention is directed to novel polypeptide, designated in the present application as “UCP4” (SEQ ID NO: 1), having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: November 8, 2012
    Publication date: March 14, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME
    Publication number: 20130064822
    Abstract: The present invention concerns antibodies to EGFL7 and the uses of same.
    Type: Application
    Filed: November 2, 2012
    Publication date: March 14, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • Anti-CD22 antibodies and immunoconjugates and methods of use
    Patent number: 8394607
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: March 12, 2013
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
  • Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
    Patent number: 8394796
    Abstract: Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: March 12, 2013
    Assignee: Genentech, Inc.
    Inventors: Georgette Castanedo, Bryan Chan, David Goldstein, Rama Kondru, Matthew Lucas, Wylie Palmer, Stephen Price, Brian Safina, Pascal Pierre Alexandre Savy, Eileen Mary Seward, Daniel P. Sutherlin, Zachary K. Sweeney
  • Pyrazole [3, 4-B] pyridine Raf inhibitors
    Patent number: 8394795
    Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: March 12, 2013
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: Kateri A. Ahrendt, Alexandre J. Buckmelter, Jason De Meese, Jonas Grina, Joshua D. Hansen, Ellen R. Laird, Paul Lunghofer, David Moreno, Brad Newhouse, Li Ren, Jeongbeob Seo, Hongqi Tian, Steven Mark Wenglowsky, Bainian Feng, Janet Gunzner, Kim Malesky, Simon Mathieu, Joachim Rudolph, Zhaoyang Wen, Wendy B. Young
  • Nucleic acid encoding fused
    Patent number: 8394939
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, immunoadhesins, agonists and antagonists (including antibodies) to human & vertebrate fused.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: March 12, 2013
    Assignee: Genentech, Inc.
    Inventors: Frederic de Sauvage, Arnon Rosenthal, Maximilien Murone
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20130058960
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: November 2, 2012
    Publication date: March 7, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY
    Publication number: 20130059859
    Abstract: A method of predicting the sensitivity of tumor cell growth to inhibition by a PI3K/AKT kinase pathway inhibitor, comprising: determining the localization profile of FOXO3a in a tumor cell, wherein a cytoplasmic localization profile of FOXO3a correlates with sensitivity to inhibition by a PI3K/AKT kinase inhibitor and a nuclear localization profile of FOXO3a correlates with resistance to inhibition by a PI3K/AKT kinase inhibitor.
    Type: Application
    Filed: October 16, 2012
    Publication date: March 7, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE
    Publication number: 20130058955
    Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.
    Type: Application
    Filed: August 6, 2012
    Publication date: March 7, 2013
    Applicant: GENENTECH, INC.
    Inventors: Robert F. Kelley, Vishva Dixit, Marissa L. Matsumoto
  • ANTI-VEGF ANTIBODIES
    Publication number: 20130058927
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Application
    Filed: October 31, 2012
    Publication date: March 7, 2013
    Applicant: GENENTECH, INC.
    Inventor: GENENTECH, INC.
  • COMPOSITIONS AND METHODS USEFUL FOR REDUCING THE VISCOSITY OF PROTEIN-CONTAINING FORMULATIONS
    Publication number: 20130058958
    Abstract: The invention relates to use of certain compounds including, for example, certain charged amino acids and structural analogs thereof, for reducing the viscosity of aqueous protein-containing formulations. Associated compositions of matter and methods of use are also contemplated within the present invention.
    Type: Application
    Filed: November 2, 2012
    Publication date: March 7, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • Compositions and methods for the treatment of tumor of hematopoietic origin
    Patent number: 8388973
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: March 5, 2013
    Assignee: Genentech, Inc.
    Inventors: Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Gretchen Frantz, Jo-Anne S. Hongo, Hartmut Koeppen, Andrew Polson, Victoria Smith
  • Process for producing Apo2L
    Patent number: 8389242
    Abstract: A process is described for producing a polypeptide heterologous to E. coli wherein E. coli cells comprising nucleic acid encoding the polypeptide are cultured in a culture medium while feeding to the culture medium a transportable organophosphate, such that the nucleic acid is expressed. The polypeptide is then recovered from the cells.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: March 5, 2013
    Assignee: Genentech, Inc.
    Inventors: Woon-Lam Susan Leung, James R. Swartz